Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis
Abstract
To the Editor: The articles by Fox et al. 1 and Hesseling et al. 2 and the editorial by Dorman 3 (Dec. 19/26 issue) on the use of levofloxacin for tuberculosis prevention underscore the many difficulties that investigators face when approaching populations at risk. Despite the strengths of the trials, the pill-counting and questionnaire methods that were used to assess adherence are known to have numerous shortcomings. 4 Given the multiple difficulties in conducting these trials, was any effort made to measure blood drug levels in trial participants? Because differences in adherence, absorption, and metabolism may play an important role in trial outcomes, pharmacokinetic . . .
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.